Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
- PMID: 15150081
- DOI: 10.1182/blood-2004-03-0804
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
Abstract
Nonmyeloablative regimens for allogeneic hematopoietic cell transplantation (HCT) have been developed for patients ineligible for myeloablative conditioning. We compared regimen-related toxicities (RRTs) and nonrelapse mortality (NRM) in 73 nonmyeloablative and 73 myeloablative recipients of HLA-matched related donor HCT, using the National Cancer Institute (NCI) Common Toxicity Criteria. Nonmyeloablative regimens were 2 Gy total body irradiation (TBI), either alone (n = 40) or combined with fludarabine, 30 mg/m(2)/d for 3 days (n = 33). Posttransplantation immunosuppression included mycophenolate mofetil and cyclosporine. Myeloablative regimens consisted mostly of cyclophosphamide + TBI or busulfan + cyclophosphamide, followed by posttransplantation methotrexate and cyclosporine. Nonmyeloablative patients were at higher risk than ablative patients because of greater age, longer time from diagnosis to HCT, more frequent preceding high-dose HCT, and higher pretransplantation Charlson comorbidity scores. Nevertheless, they experienced significantly less severe toxicities in 7 organs/systems: hematologic, gastrointestinal, hepatic, hemorrhage, infection, metabolic, and pulmonary. This translated into less NRM at day 100 (3% versus 23%, P = 10(-4)) and 1 year (16% versus 30%, P =.04). In multivariate analysis, the strongest factor predicting lessened RRT and NRM was nonmyeloablative conditioning, whereas high pretransplantation comorbidity scores predicted higher NRM. In conclusion, nonmyeloablative regimens had lower RRT and NRM and could be considered for comparative studies, including younger patients with more favorable Charlson comorbidity scores.
Similar articles
-
Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.Blood. 2004 Aug 15;104(4):961-8. doi: 10.1182/blood-2004-02-0545. Epub 2004 Apr 27. Blood. 2004. PMID: 15113759
-
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.Biol Blood Marrow Transplant. 2018 Aug;24(8):1733-1740. doi: 10.1016/j.bbmt.2018.03.011. Epub 2018 Mar 16. Biol Blood Marrow Transplant. 2018. PMID: 29555313
-
Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.Am J Kidney Dis. 2005 Mar;45(3):502-9. doi: 10.1053/j.ajkd.2004.11.013. Am J Kidney Dis. 2005. PMID: 15754272
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.Semin Hematol. 2006 Apr;43(2 Suppl 2):S35-43. doi: 10.1053/j.seminhematol.2005.12.007. Semin Hematol. 2006. PMID: 16549113 Review.
Cited by
-
Optimization of nutrition support practices early after hematopoietic cell transplantation.Bone Marrow Transplant. 2021 Feb;56(2):314-326. doi: 10.1038/s41409-020-01078-9. Epub 2020 Oct 10. Bone Marrow Transplant. 2021. PMID: 33040076 Review.
-
Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study.Bone Marrow Transplant. 2023 Jun;58(6):667-672. doi: 10.1038/s41409-023-01947-z. Epub 2023 Mar 13. Bone Marrow Transplant. 2023. PMID: 36914730
-
Survival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing Outcomes.Biol Blood Marrow Transplant. 2016 Aug;22(8):1525-1530. doi: 10.1016/j.bbmt.2016.05.012. Epub 2016 May 17. Biol Blood Marrow Transplant. 2016. PMID: 27223110 Free PMC article.
-
Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease.J Clin Med. 2022 Jul 3;11(13):3856. doi: 10.3390/jcm11133856. J Clin Med. 2022. PMID: 35807140 Free PMC article. Review.
-
Non-myeloablative allogeneic hematopoietic stem cell transplantation.Semin Oncol Nurs. 2009 May;25(2):120-8. doi: 10.1016/j.soncn.2009.03.006. Semin Oncol Nurs. 2009. PMID: 19411015 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials